WallStSmart

Elevai Labs, Inc. Common Stock (ELAB)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 211973% more annual revenue ($606.42M vs $285,950). ELAB leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

ELAB

Avoid

25

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -0.72

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELAB1 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ELAB4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.91M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-76.2%2/10

ROE of -76.2% — below average capital efficiency

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ELAB

The strongest argument for ELAB centers on Price/Book.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : ELAB

The primary concerns for ELAB are EPS Growth, Market Cap, Profit Margin.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

ELAB profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

ELAB generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elevai Labs, Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Elevai Labs, Inc. (Ticker: ELAB) is a cutting-edge technology company focused on revolutionizing artificial intelligence and machine learning applications. With its advanced data analytics platforms, Elevai Labs facilitates enhanced decision-making across key sectors, particularly in healthcare and finance, enabling organizations to extract actionable insights from complex datasets. Positioned at the forefront of the rapidly evolving tech landscape, the company is well-equipped to capitalize on emerging trends, thereby delivering significant value and operational efficiency to its clients and stakeholders.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?